Literature DB >> 18716625

Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

Xiaocong Yu1, Tshidi Tsibane, Patricia A McGraw, Frances S House, Christopher J Keefer, Mark D Hicar, Terrence M Tumpey, Claudia Pappas, Lucy A Perrone, Osvaldo Martinez, James Stevens, Ian A Wilson, Patricia V Aguilar, Eric L Altschuler, Christopher F Basler, James E Crowe.   

Abstract

Investigation of the human antibody response to influenza virus infection has been largely limited to serology, with relatively little analysis at the molecular level. The 1918 H1N1 influenza virus pandemic was the most severe of the modern era. Recent work has recovered the gene sequences of this unusual strain, so that the 1918 pandemic virus could be reconstituted to display its unique virulence phenotypes. However, little is known about adaptive immunity to this virus. We took advantage of the 1918 virus sequencing and the resultant production of recombinant 1918 haemagglutinin (HA) protein antigen to characterize at the clonal level neutralizing antibodies induced by natural exposure of survivors to the 1918 pandemic virus. Here we show that of the 32 individuals tested that were born in or before 1915, each showed seroreactivity with the 1918 virus, nearly 90 years after the pandemic. Seven of the eight donor samples tested had circulating B cells that secreted antibodies that bound the 1918 HA. We isolated B cells from subjects and generated five monoclonal antibodies that showed potent neutralizing activity against 1918 virus from three separate donors. These antibodies also cross-reacted with the genetically similar HA of a 1930 swine H1N1 influenza strain, but did not cross-react with HAs of more contemporary human influenza viruses. The antibody genes had an unusually high degree of somatic mutation. The antibodies bound to the 1918 HA protein with high affinity, had exceptional virus-neutralizing potency and protected mice from lethal infection. Isolation of viruses that escaped inhibition suggested that the antibodies recognize classical antigenic sites on the HA surface. Thus, these studies demonstrate that survivors of the 1918 influenza pandemic possess highly functional, virus-neutralizing antibodies to this uniquely virulent virus, and that humans can sustain circulating B memory cells to viruses for many decades after exposure-well into the tenth decade of life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716625      PMCID: PMC2848880          DOI: 10.1038/nature07231

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  28 in total

1.  Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic.

Authors:  Niall P A S Johnson; Juergen Mueller
Journal:  Bull Hist Med       Date:  2002       Impact factor: 1.314

2.  Maintenance of serological memory by polyclonal activation of human memory B cells.

Authors:  Nadia L Bernasconi; Elisabetta Traggiai; Antonio Lanzavecchia
Journal:  Science       Date:  2002-12-13       Impact factor: 47.728

3.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

4.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

5.  IMGT, the international ImMunoGeneTics database.

Authors:  M Ruiz; V Giudicelli; C Ginestoux; P Stoehr; J Robinson; J Bodmer; S G Marsh; R Bontrop; M Lemaitre; G Lefranc; D Chaume; M P Lefranc
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

6.  Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950.

Authors:  K Nakajima; U Desselberger; P Palese
Journal:  Nature       Date:  1978-07-27       Impact factor: 49.962

7.  Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles.

Authors:  Jörn Hendrik Weitkamp; Nicole Kallewaard; Koichi Kusuhara; Dino Feigelstock; Ninguo Feng; Harry B Greenberg; James E Crowe
Journal:  J Immunol Methods       Date:  2003-04-01       Impact factor: 2.303

8.  The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin.

Authors:  G G Brownlee; E Fodor
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

9.  Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

Authors:  Terrence M Tumpey; Adolfo García-Sastre; Andrea Mikulasova; Jeffery K Taubenberger; David E Swayne; Peter Palese; Christopher F Basler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

10.  Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus.

Authors:  James Stevens; Adam L Corper; Christopher F Basler; Jeffery K Taubenberger; Peter Palese; Ian A Wilson
Journal:  Science       Date:  2004-02-05       Impact factor: 47.728

View more
  183 in total

1.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

Review 2.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

3.  Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses.

Authors:  Natalie J Thornburg; David P Nannemann; David L Blum; Jessica A Belser; Terrence M Tumpey; Shyam Deshpande; Gloria A Fritz; Gopal Sapparapu; Jens C Krause; Jeong Hyun Lee; Andrew B Ward; David E Lee; Sheng Li; Katie L Winarski; Benjamin W Spiller; Jens Meiler; James E Crowe
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

5.  Instant immunity through chemically programmable vaccination and covalent self-assembly.

Authors:  Mikhail Popkov; Beatriz Gonzalez; Subhash C Sinha; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

6.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

7.  Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.

Authors:  Roger R Beerli; Monika Bauer; Andrea Fritzer; Lindsey B Rosen; Regula B Buser; Markus Hanner; Melanie Maudrich; Mario Nebenfuehr; Jorge Alejandro Sepulveda Toepfer; Susanne Mangold; Anton Bauer; Steven M Holland; Sarah K Browne; Andreas Meinke
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 8.  History of passive antibody administration for prevention and treatment of infectious diseases.

Authors:  Barney S Graham; Donna M Ambrosino
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

Review 9.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

10.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.